Skip to main
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics has demonstrated significant progress with its Phase 2b PARADIGM study, achieving a statistically significant 29.2% reduction in disease progression for those treated with its lead product candidate, PrimeC. The company is also advancing its regulatory efforts to secure Canadian approval, with prospects for a 2026 launch, further enhancing its market position in neurodegenerative diseases. Furthermore, the favorable safety profile of PrimeC across its studies effectively de-risks the program, promising increased opportunities for strategic partnerships in North America and Europe that could provide non-dilutive capital for future growth.

Bears say

NeuroSense Therapeutics is facing a challenging financial situation, as its cash reserves are diminishing, indicating potential liquidity issues that could hinder ongoing operations and development. The anticipation of a necessary capital raise suggests that the company may struggle to fund its clinical initiatives and sustain growth without external financing. This financial strain, coupled with the inherent risks of clinical-stage biotechnology firms, contributes to a negative outlook for NeuroSense Therapeutics's stock.

NRSN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 1 analysts, NRSN has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.